Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.66 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.66 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12043351 | 0.80 | CHRM2 (1.00) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL8402584 | 0.71 | CHRM2 (1.00) | CHRM2CHRM3CHRM1 | |
| SCHEMBL25649112 | 0.70 | CHRM2 (0.47) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL8400708 | 0.70 | CHRM2 (0.66) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL9458794 | 0.67 | CHRM2 (0.47) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL13490567 | 0.67 | CCR1 (0.48) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL9521006 | 0.67 | CHRM2 (0.50) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL8400217 | 0.66 | CHRM2 (0.49) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL8716712 | 0.66 | CHRM2 (0.45) | CHRM2CHRM3HTR2AHTR2CHTR2B | |
| SCHEMBL21193038 | 0.64 | CHRM2 (0.44) | CHRM2CHRM3HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE36374-E | 1,2,3-triazole and tetrazole substituted piperidine or tetrahydropyridine compounds useful as acetylcholine agonists | H. LUNDBECK, A/S (DK) | 1999-11-02 | — | — | US | claimed |
| EP-0296721-B1 | HETEROCYCLIC COMPOUNDS | H. LUNDBECK A/S (DK) | 1993-06-23 | — | — | EP | claimed |
| US-4866077-A | TREATMENT OF NERVOUS SYSTEM DISORDERS SUCH AS ALZHEIMER*S DISEASE | H. LUNDBECK A/S (DK) | 1989-09-12 | — | — | US | claimed |
| EP-0296721-A2 | Heterocyclic compounds | H. LUNDBECK A/S (DK) | 1988-12-28 | — | — | EP | claimed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-RE36374-E | 1,2,3-triazole and tetrazole substituted piperidine or tetrahydropyridine compounds useful as acetylcholine agonists | H. LUNDBECK, A/S (DK) | 1999-11-02 | — | — | US | disclosed |
| EP-0296721-B1 | HETEROCYCLIC COMPOUNDS | H. LUNDBECK A/S (DK) | 1993-06-23 | — | — | EP | disclosed |
| US-4925858-A | NERVOUS SYSTEM DISORDERS, ALZHEIMER*S DISEASE | H. LUNDBECK A/S (DK) | 1990-05-15 | — | — | US | disclosed |
| US-4866077-A | TREATMENT OF NERVOUS SYSTEM DISORDERS SUCH AS ALZHEIMER*S DISEASE | H. LUNDBECK A/S (DK) | 1989-09-12 | — | — | US | disclosed |
| EP-0296721-A2 | Heterocyclic compounds | H. LUNDBECK A/S (DK) | 1988-12-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | CHRM2 15/4885CHRM3 12/4885HTR2A 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.